NasdaqGS - Nasdaq Real Time Price ? USD Denali Therapeutics Inc. (DNLI) Follow Compare 29.55 +1.90 (+6.87%) At close: 4:00 PM EST 29.55 0.00 (0.00%) After hours: 4:21 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights. "As leaders in pioneering a new class of therapeutics that cross the blood-brain barrier, we are making significant progress across our Transport Vehicle (TV)-enabled portfolio,” said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. “Within our Enzyme TV (ETV) fra GlobeNewswire ? 2 hours ago DNLI +6.87% Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 7 days ago RCUS +2.88% DNLI +6.87% Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 8 days ago DNLI +6.87% Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now We recently compiled a list of the 8 Stocks Jeff Bezos is Buying. In this article, we are going to take a look at where Denali Therapeutics Inc. (NASDAQ:DNLI) stands against the other stocks Jeff Bezos is buying. ‘We are Famously Unprofitable’ Jeff Bezos is a name closely tied to Amazon the company he reportedly founded […] Insider Monkey ? 24 days ago DNLI +6.87% Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength? Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Zacks ? 30 days ago VYGR DNLI +6.87% Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. Zacks ? last month DNLI +6.87% BPMC +2.13% Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? last month KYMR DNLI +6.87% SNY Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound? Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? 2 months ago MYGN DNLI +6.87% Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval. Zacks ? 2 months ago DNLI +6.87% Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report? BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? 2 months ago BMRN DNLI +6.87% High-dose Spinraza meets study goal; Top Dyne executives exit A new dose regimen of Biogen's spinal muscular atrophy drug appeared promising, while Denali Therapeutics and Regenxbio charted plans for drug approval applications. BioPharma Dive ? 2 months ago DYN NVO DNLI +6.87% Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) Recent successful meeting with the FDA provides path to file for accelerated approval and subsequent conversion to full approvalPlan to submit biologics license application (BLA) early in 2025 under the accelerated approval pathwayNew Phase 1/2 data will be presented this week at SSIEM 2024 demonstrating robust and durable biomarker responses and positive effects on clinical outcomes SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today ann GlobeNewswire ? 2 months ago DNLI +6.87% Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders will doubtless be very grateful to see the share price up 31% in... Simply Wall St. ? 2 months ago DNLI +6.87% Genetic testing in Parkinson’s disease patients: a standard of care imperative? Data from Centogene’s gene profiling study suggests the advantages of identifying gene variants in Parkinson’s patients are vast. Medical Device Network ? 2 months ago CNTG DNLI +6.87% Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration SOUTH SAN FRANCISCO, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced publication of nonclinical data in the August 14, 2024 issue of Science Translational Medicine (link) demonstrating the ability of the Oligonucleotide Transport Vehicle (OTV) platf GlobeNewswire ? 2 months ago DNLI +6.87% Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade The consensus price target hints at a 79.6% upside potential for Denali Therapeutics (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Zacks ? 2 months ago DNLI +6.87% Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2024, and provided business highlights. "In the second quarter, our Enzyme Transport Vehicle franchise gained additi GlobeNewswire ? 3 months ago DNLI +6.87% Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. Zacks ? 3 months ago DNLI +6.87% AMRN Denali Therapeutics Stock Gets Technical Rating Upgrade Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Investor's Business Daily ? 3 months ago DNLI +6.87% 3 Longevity Stocks to Buy for Anti-Aging Breakthroughs The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago. As a result, Crispen-based treatments meant to target age-related genomic changes are in development. Leading organizations are looking at methods to fix aging DNA, and businesses are using artificial intelligence to find molecules that either halt or slow down aging. These discoveries and more are enabling InvestorPlace ? 3 months ago DNLI +6.87% 002722.SZ RXRX Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return DNLI S&P 500 YTD +37.70% +24.30% 1-Year +35.36% +36.04% 3-Year -46.29% +26.22%
